期刊文献+

艾司西酞普兰与帕罗西汀治疗伴有焦虑症状抑郁障碍的对照研究 被引量:6

Comparison study of Escitalopram vs Paroxetine in the treatment of depressive disorder with anxiety
暂未订购
导出
摘要 目的:研究艾司西酞普兰与帕罗西汀治疗伴有焦虑症状抑郁障碍的疗效及安全性。方法:将64例伴焦虑症状的抑郁障碍患者随机进人艾司西酞普兰组(n=32)或帕罗西汀组(n=32)接受为期6周治疗,分别在治疗第0、1、2、4、6周末以《汉米尔顿抑郁量表-17》(Hamilton Depression Rating Scale for Depression-17,HRSD)及《汉米尔顿焦虑量表》(Hamilton Anxiety Scale,HAMA)总分评估患者疗效,以《药物副反应量表》(Treatment Emergent Symptom Scal,TESS)评估患者的药物不良反应。脱落患者数据视为不可用,不予统计。结果:经过6周的治疗,艾司西酞普兰组脱落1例,帕罗西汀组脱落2例,两者之间无明显差异(P>0.05)。艾司西酞普兰组有效率和治愈率分别是83.9%(26例)和58.1%(18例)。帕罗西汀组有效率和治愈率分别是76.7%(23例)和56.7%(17例),两组无明显差异(P>0.05)。治疗第1、2周末艾司西酞普兰组HAMD量表总分改善明显好于帕罗西汀组(P<0.01),第4周、第6周则无明显差异(P>0.05)。治疗第1周HAMA量表艾司西酞普兰组总分好于帕罗西汀组(P<0.05)。不良反应艾司西酞普兰组明显少于帕罗西汀组(x2值=14.93;P值<0.001)。结论:艾司西酞普兰与帕罗西汀疗效相当,艾司西酞普兰起效较快,早期即有明确的抗抑郁及焦虑作用;且不良反应发生率低。 Objective:To evaluate the efficacy and safety of Escitalopram vs Paroxetine in the treatment of depressive disorder with anxiety. Methods:This was an 6 weeks randomized control study. Totally 64 patients were randomly assigned to Escitalopram group ( n = 32) or Paroxetin group ( n = 32). Clinical efficacies were assessed with the Hamilton Depression Scale (HRSD) and Hamilton Anxiety Scale (HAMA). adverse actions with the Treatment Emergent Symptom Scale (TESS) before and at the end of the 1 st,2nd ,4th and 6th week treatment. Results: The 6 - week drop in Escitalopram group was lower than that in Paroxetine group ( 1 VS. 2, P 〉 0. 05) ,which showed no significant difference. In patients who completed 6 - week trial,the difference of symptom improvement rate be- tween Escitalopram group and Paroxetin group was not statistically significant( P 〉 0.05 ). Analysis showed that at the end of 6 - weeks observation,there was no statistically difference in efficacy between the two groups. But Escitalopram group showed earlier improvement in depressive symptoms and Anxiety symptoms than Paroxetine group. ( HRSD score at the end of the lth week and 2nd week, ( 16.24±3.82) VS (20.72± 3.16), P 〈 0.01, ( 13.3 ± 5.4) VS ( 17.1 ±6.3), P 〈 0.01 ; HAMA score at the end of the 1 th week, ( 13.14 ± 5.4) VS ( 14.8 ± 6.1 ) ,P 〈 0.05 ) , and lower adverse reactions than Paroxetine group ( 12VS26, x2 = 14.93, P 〈 O. 001 ). Conclu- sions: Both Escitalopram and Paroxetine have same efficacy. Escitalopram in the treatment of depressive disorder with anxiety may have better efficacy and tolerance than Paroxetine.
机构地区 徐州精神病院
出处 《中国民康医学》 2012年第23期2843-2846,共4页 Medical Journal of Chinese People’s Health
关键词 抑郁障碍 焦虑 艾司西酞普兰 帕罗西汀 汉米尔顿抑郁量表 汉米尔顿焦虑量表 不良反应量表 Depressive disorder Anxiety Escitalopram Paroxetine HRSD HAMA Tess
  • 相关文献

参考文献12

  • 1Zajecka JM, Ross JS. A systematized approach to the management of the depressed and anxious patient [ J ]. Int J Clin Practice, 1998,2:27 - 30.
  • 2Fawcett J. Predictors of early suicide :identification and appropriate intervention [ J ]. J Clin Psychiatry, 1988, ( suppl 49 ) :7 - 8.
  • 3Owens M J, Knight DL, Nemeroff CB. Second generation SSRIs: hu- man monoamine transporter binding profile of escitalopram and R - fluoxetine[ J]. Biol Psychiatry,2001,50:345 - 350.
  • 4Murdoch D, Keam SJ. Escitalopram:areview of its use in the man- agement of major depressive disorder[ J ]. Drugs,2005,65:2379 - 2404.
  • 5Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysisof placebo - controlled trials [ J ]. CNS Spectr, 2002,7 (Suppl) :40 -44.
  • 6范肖冬 汪向东 于欣 译.ICD-10精神与行为障碍分类[M].北京:人民卫生出版社,1993.197.
  • 7.汤毓华.汉密尔顿抑郁量表[J].中国心理卫生杂志,1993,(增刊):186-190.
  • 8汤毓华.汉密尔顿焦虑量表.中国心理卫生杂志,1993,:220-223.
  • 9司天梅,舒良.关于新抗抑郁药艾司西酞普兰[J].临床精神医学杂志,2007,17(1):68-69. 被引量:126
  • 10Thase ME. The Concept of Remission: validity and limitations [ J ]. J Clin Psychiatry,2006,67:478 - 481.

二级参考文献14

  • 1Owens MJ,Knight DL,Nemeroff CB.Second generation SSRIs:human monoamine transporter binding profile of escitalopram and R-fluoxetine[J].Biol Psychiatry,2001,50:345-350.
  • 2Chen FH,Larsen MB,Sanchezc,et al.The S-enantiomer of R,S-citalopram,increases inhibitor binding to the human serotonin transporter by an allosteric mechanism.Comparison with other serotonin transporter inhibitors[J].Eur Neuropsychopharmacology,2005,15:193-198.
  • 3Mork A,Kreilgaard M,Sanchez C.The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats[J].Neuropharmacology,2003,45:167-173.
  • 4Sanchez C.R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalization model[J].Eur J Pharmacol,2003,464:155-158.
  • 5Sanchez C,Gruca P,Papp M.R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model of depression[J].Behav Pharmacol,2003,14:465-470.
  • 6Plenge P,Mellerup ET,Laursen H.Affinity modulation of[^3H]imipramine,[^3H]paroxetine and[^3H]citalopram binding to the 5-HT transporter from brain and platelets[J].Eur J Pharmacol,1991,206:243-250.
  • 7Fava M,Davidson KG.Definition and epidemiology of treatment resistant depression[J].Psychiatr Clin North Am,1996,19:179-200.
  • 8Thase ME.The Concept of Remission:validity and limitations[J].JClin Psychiatry,2006,67:478-481.
  • 9Thase ME.Evaluating antidepressant therapies:Remission as the optimal outcome[J].J Clin Psychiatry,2003,64(Suppl 13):18-25.
  • 10Murdoch D,Keam SJ.Escitalopram:a review of its use in the management of major depressive disorder[J].Drugs,2005,65:2379-2404.

共引文献251

同被引文献69

  • 1郭怡菁,杨玲俐,隋毓秀,张志珺.卒中后抑郁的发病机制[J].中国卒中杂志,2007,2(11):912-915. 被引量:22
  • 2许晶,王俊平,刘晶.脑卒中后抑郁障碍的规范化诊断[J].中国行为医学科学,2006,15(2):135-135. 被引量:17
  • 3刘华莉,杜海英,刘玉,李红.西酞普兰治疗老年期抑郁症疗效观察[J].临床精神医学杂志,2006,16(2):88-89. 被引量:15
  • 4沈渔邮.精神病学[M].北京:人民卫生出版社2009(5).
  • 5江开达.精神病学[M].北京:人民卫生版社,2007,420-421.
  • 6沈渔郦.精神病学[M].5版.北京:人民卫生出版社,2009:503-504.
  • 7李淑梅.艾司西酞普兰与舍曲林治疗抑郁症疗效比较[J].中国药师,20lO,13(8):l168.
  • 8Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause1990-2020:Global Burden of Disease Study[J]. Lancet, 1997,349(9064): 1498-1504.
  • 9Zimmerman M, Chelminski I, Mcdermut W.Major depression disorder and axis I diagnostic comorbidity[J]. J Clin Psychiatry, 2002,63(3):187-193.
  • 10Altamura A C, Montresor C, Salvadori D, et al. Does comorbid subthreshold anxiety affect clinical presentation and treatment response in depression?A preliminary 12-month naturalistic study[J] Int J Neuropsychopharmacol, 2004,7(4):481-487.

引证文献6

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部